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research planning exercise. METHODS: The Atrial Fi-
brillation Antithrombosis Model (AFAM) provides esti-
mates of health and cost outcomes for up to four compet-
ing, user-defined antithrombosis (AT) strategies that may
be used for individuals with atrial fibrillation (AF). These
include conventional anticoagulation (AC) or enhanced
AT such as improved management of a conventional cou-
marin anticoagulant (e.g., warfarin provided through AC
services) or a new agent with some clinical advantage.
Each strategy is characterized by: (1) patient eligibility
pattern, (2) efficacy, (3) impact on quality of life; (4) dis-
continuation rate; and (5) initial and recurrent cost.
AFAM is based on the Duke Stroke Policy Model (SPM),
a validated natural history simulation that projects the
health and cost outcomes of individuals at risk for stroke
and those who have experienced stroke. As a demonstra-
tion, we applied the model to a research planning exer-
cise. Using AFAM we calculated the threshold efficacy
that would lead to an EAT that is cost-effective (i.e., in-
cremental CE ratio of $50,000.) RESULTS: Assuming
an EAT costs 50% greater than AC, and the relative risk
of stroke for AC is 0.6, then EAT would be cost-effective
if the relative risk for stroke is no less than 0.95. In absolute
terms, a cost-effective EAT would need to reduce annual
stroke risk from 3% down to 2.85%. CONCLUSIONS:
The AFAM takes advantage of a previously developed,
validated natural history simulation model. With relative
ease this can be used to facilitate research planning, trial
analysis and education. Its present application serves to
demonstrate that treatments that are only modestly superior
to existing therapies for stroke prevention can be cost-
effective.
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While cyclöoxygenase-2 inhibitors appear to be safe, hy-
pertensive persons who use rofecoxib may experience in-
creases in systolic blood pressure (SBP). In a randomized
clinical trial involving hypertensive osteoarthritic sub-
jects, use of rofecoxib 25 mg was associated with a 3 mm Hg
increase in systolic blood pressure versus celecoxib 200 mg.
Increased SBP among users of rofecoxib may be associ-
ated with increased risk of cardiovascular disease. OB-
JECTIVE: To estimate excess coronary heart disease
(CHD) and stroke morbidity and mortality associated
with a 3 mm Hg increase in SBP among U.S. adults with
hypertension and osteoarthritis. METHODS: We used
cardiovascular risk prediction models from the Framing-
ham Heart Study and risk factor data from the Third Na-
tional Health and Nutrition Examination Survey to esti-
mate occurrences of CHD and stroke over four years
among osteoarthritic persons with hypertension. We then
estimated the effect of a 3 mm Hg increase in SBP on
event occurrence and costs of cardiovascular disease treat-
ment. RESULTS: An estimated 10.2 million U.S. osteoar-
thritics aged 35 years are hypertensive. Among such
persons, a 3 mm Hg increase in SBP may be associated
with 20,800 additional CHD events (22% fatal) and
21,600 additional stroke events (26% fatal) over four
years. The total cost of treating these events over four
years is estimated to exceed US$650 million in year 2000
constant dollars. CONCLUSION: Increases in SBP asso-
ciated with use of rofecoxib versus celecoxib may trans-
late into significant cardiovascular morbidity and mortal-
ity and impose a sizable economic burden.
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OBJECTIVES: Clinical and epidemiological evidence has
been accumulating for a link between Chlamydia pneu-
moniae and coronary heart disease, but as yet causality is
unproven. The aim of this study was to explore the po-
tential impact and cost-effectiveness of a program of
screening and treatment for C. pneumoniae, assuming a
causal relationship, with a view to informing investment
in definitive trials. METHOD: A spreadsheet model was
used to estimate the impact of different strategies for
screening and treating C. pneumoniae on the incidence of
myocardial infarction and cardiac mortality over a 1-year
post-intervention period, under a range of assumptions.
RESULTS: Screening would potentially be most cost-effec-
tive in patients aged 35 or more with a history of myo-
cardial infarction (central estimate around £3000 per life-
year saved.). Cost-effectiveness will be similar in those
aged 75–84 with established heart disease but no history
of MI, but inferior for younger patients of this kind, and
poorer for people at elevated CHD risk. Sensitivity analy-
sis confirmed that the factors that affect the additional
cost of treatment of survivors of CHD (e.g. length of sur-
vival after prevented death, annual treatment cost for
people with CHD) were all important. The factors that
determine the cost of the screening program (e.g. dura-
tion and daily cost of antibiotic treatment) were also im-
portant, but less so. The results were less sensitive to the
positive predictive value of screening and compliance
with treatment, but these are variables for which wide
ranges of values are plausible. CONCLUSIONS: If cau-
sality of the association between C. pneumoniae and
heart disease were proven, this speculative model sug-
gests that the likely range of costs per life-year saved of a
program of identification and treatment of C. pneumo-
niae targeted at post-MI patients aged 35 or more would
